Robert W. Baird Raises MEDNAX (MD) Price Target to $54.00
MEDNAX (NYSE:MD) had its target price boosted by research analysts at Robert W. Baird from $48.00 to $54.00 in a note issued to investors on Friday. The firm presently has a “neutral” rating on the stock. Robert W. Baird’s price target indicates a potential downside of 1.33% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Stephens set a $62.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research note on Thursday. Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Tuesday. Mizuho set a $49.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Citigroup decreased their price target on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $56.00 price target on shares of MEDNAX in a research report on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $54.75.
Shares of MEDNAX (MD) traded up $2.17 during midday trading on Friday, hitting $54.73. 269,270 shares of the stock traded hands, compared to its average volume of 881,366. MEDNAX has a one year low of $40.56 and a one year high of $72.13. The stock has a market cap of $4,920.00, a PE ratio of 15.86, a PEG ratio of 1.40 and a beta of 0.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. Thompson Siegel & Walmsley LLC boosted its position in MEDNAX by 19.7% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after buying an additional 428,184 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of MEDNAX by 4.8% in the 3rd quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after purchasing an additional 106,883 shares in the last quarter. Earnest Partners LLC raised its stake in shares of MEDNAX by 0.7% in the 3rd quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock valued at $64,437,000 after purchasing an additional 11,037 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of MEDNAX by 25.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,424,574 shares of the company’s stock valued at $61,428,000 after purchasing an additional 293,011 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of MEDNAX by 74.9% in the 4th quarter. Wells Fargo & Company MN now owns 838,882 shares of the company’s stock valued at $44,830,000 after purchasing an additional 359,288 shares in the last quarter. 98.67% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/02/09/robert-w-baird-raises-mednax-md-price-target-to-54-00.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.